$2.17
+0.09 (+4.33%)
Open$2.16
Previous Close$2.08
Day High$2.22
Day Low$2.12
52W High$4.99
52W Low$0.56
Volume—
Avg Volume809.4K
Market Cap73.92M
P/E Ratio—
EPS$-1.26
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+552.5% upside
Current
$2.17
$2.17
Target
$14.16
$14.16
$9.87
$14.16 avg
$18.59
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.36M | 2.28M | 19.24M |
| Net Income | -62,509,764 | -94,235,825 | -3,136,016 |
| Profit Margin | -4,594.3% | -4,364.5% | -16.3% |
| EBITDA | -60,706,323 | -96,601,351 | -4,591,050 |
| Free Cash Flow | — | — | -2,958,449 |
| Rev Growth | -40.3% | -40.3% | -5.9% |
| Debt/Equity | 0.91 | 0.91 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |